Home Conference Coverage

Conference Coverage

What to Expect at SABCS 2020: New Data for HER2 and HER3 Directed DXd...

New research data for trastuzumab deruxtecan (fam-trastuzumab deruxtecan-nxki; Enhertu®; Daiichi Sankyo) and patritumab deruxtecan (U3-1402; HER3-DXd), two DXd antibody-drug...

Seagen Presents Broad Portfolio of Innovative Immuno-Oncology Data – Featuring Sugar-Engineered Antibodies

During the upcoming 35th annual meeting of the Society for Immunotherapy of Cancer’s (SITC) being held November 9-14, 2020,...

The 7th Annual World ADC Awards Winners – What’s Next

The World ADC Awards showcase companies, teams, and individuals in the industry, across 9 categories, at the forefront of...

ESMO 2020: Study Shows Meaningful Clinical Activity with Tisotumab Vedotin in Cervical Cancer

Tisotumab vedotin, an investigational agent is being developed by Seattle Genetics and Genmab, shows meaningful clinical activity as monotherapy...

ESMO 2020: In Heavily-pretreated Metastatic Urothelial Cancer Sacituzumab Govitecan Shows 27% ORR

Heavily-pretreated, cisplatin-eligible, patients benefit from treatment with sacituzumab govitecan (sacituzumab govitecan-hziy; Trodelvy®; Immunomedics). This is the conclusion from an analysis...
ESMO 2017 - 3

ESMO 2020: Sacituzumab Govitecan Shows Encouraging Early-Stage Clinical Results in Brain Cancer

A clinical trial (NCT03995706) studying the extent by which sacituzumab govitecan (Trodelvy™; Immunomedics) is able to get into the...

ESMO 2020: Updated Interim Data of XMT-1536 Supports Continued Development in Ovarian Cancer

Updated interim phase I date for the safety, tolerability, and efficacy porting for the ovarian cancer cohort of an...

ESMO 2020: XMT-1536 Shows 34% ORR in Phase I Expansion Study in Ovarian Cancer

Updated interim safety, tolerability, and efficacy data for the ovarian cancer cohort of the ongoing expansion portion of the...

In vivo data Shows Efficacy of Synaffix’ Proprietary Exatecan Linker-Payload to be on par...

In a poster presented during the virtual World ADC meeting, being held September 15 - 17, 2020 scientists at...
General images of ESMO 2019 Congress being held in Barcelona, Spain, September 27 - October 1, 2019. Courtesy European Society for Medical Oncology (ESMO). Used with Permission.

ESMO 2020: Late-Breaking Data for HER3 Directed ADC Patritumab Deruxtecan in EGFR Mutated NSCLC

Data for patritumab deruxtecan (U3-1402; Daiichi Sankyo) and fam-trastuzumab deruxtecan-nxki* (Enhertu®; Daiichi Sankyo/AstraZeneca), two antibody-drug conjugates (ADC) based on...